{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:26Z","timestamp":1790912486985,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003132","name":"Flemish Agency for Innovation by Science and Technology","doi-asserted-by":"publisher","award":["150274"],"award-info":[{"award-number":["150274"]}],"id":[{"id":"10.13039\/501100003132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jvacx.2019.100007","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:36:00Z","timestamp":1548808560000},"page":"100007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7704-0527","authenticated-orcid":false,"given":"Kaatje","family":"Bollaerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alexandridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Verstraeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2019.100007_b0005","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/bmj.326.7392.748","article-title":"Treatment of herpes zoster and postherpetic neuralgia","volume":"326","author":"Johnson","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jvacx.2019.100007_b0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jvacx.2019.100007_b0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.jvacx.2019.100007_b0020","unstructured":"European Medicines Agency. Zostavax (shingles [herpes zoster]) vaccine [live]): summary of product characteristics. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000674\/WC500053462.pdf>."},{"key":"10.1016\/j.jvacx.2019.100007_b0025","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2019.100007_b0030","unstructured":"Public Health England. Herpes zoster (shingles) immunisation programme 2013\/2014: Report for England. Available from: <https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/383018\/ShinglesReport2014.pdf>."},{"key":"10.1016\/j.jvacx.2019.100007_b0035","doi-asserted-by":"crossref","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","article-title":"Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study","volume":"131","author":"Baxter","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jvacx.2019.100007_b0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/ciw854","article-title":"Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older","volume":"64","author":"Izurieta","year":"2017","journal-title":"Clin Infect Dis Official Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jvacx.2019.100007_b0045","doi-asserted-by":"crossref","first-page":"e1001420","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.jvacx.2019.100007_b0050","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/21645515.2015.1016681","article-title":"Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status","volume":"11","author":"Marin","year":"2015","journal-title":"Human Vaccines Immunotherapeutics"},{"key":"10.1016\/j.jvacx.2019.100007_b0055","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2468-2667(17)30234-7","article-title":"Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study","volume":"3","author":"Amirthalingam","year":"2018","journal-title":"Lancet Publ Health"},{"issue":"17","key":"10.1016\/j.jvacx.2019.100007_b0060","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.vaccine.2018.02.021","article-title":"Effectiveness of herpes zoster vaccination in an older United Kingdom population","volume":"36","author":"Walker","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100007_b0065","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.vaccine.2014.10.047","article-title":"The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines","volume":"33","author":"Lopalco","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100007_b0070","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: clinical practice research datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jvacx.2019.100007_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the general practice research database: a systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jvacx.2019.100007_b0080","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/ije\/dyx015","article-title":"Data resource profile: hospital episode statistics admitted patient care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jvacx.2019.100007_b0085","doi-asserted-by":"crossref","first-page":"g2911","DOI":"10.1136\/bmj.g2911","article-title":"Quantification of risk factors for herpes zoster: population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jvacx.2019.100007_b0090","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/bjd.16399","article-title":"Inequalities in zoster disease burden: a population-based cohort study to identify social determinants using linked data from the UK Clinical Practice Research Datalink","volume":"178","author":"Jain","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jvacx.2019.100007_b0095","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1542\/peds.112.2.e98","article-title":"A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination","volume":"112","author":"Verstraeten","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.jvacx.2019.100007_b0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s15010-007-6347-x","article-title":"Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel","volume":"36","author":"Heymann","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.jvacx.2019.100007_b0105","doi-asserted-by":"crossref","first-page":"E275","DOI":"10.1503\/cmaj.101137","article-title":"Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study","volume":"183","author":"Yang","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.jvacx.2019.100007_b0110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","article-title":"Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study","volume":"87","author":"Forbes","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jvacx.2019.100007_b0115","unstructured":"Public Health England. Immunisation against infectious disease. The Green Book. Chapter 28a: Shingles. Available from: <https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/503773\/2905109_Green_Book_Chapter_28a_v3_0W.PDF>."},{"key":"10.1016\/j.jvacx.2019.100007_b0120","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/21645515.2016.1164362","article-title":"Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus","volume":"12","author":"Van Der Meeren","year":"2016","journal-title":"Human Vaccines Immunotherapeutics"},{"key":"10.1016\/j.jvacx.2019.100007_b0125","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1016\/j.vaccine.2012.02.078","article-title":"Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak","volume":"30","author":"Williams","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100007_b0130","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1016\/j.vaccine.2017.01.071","article-title":"Post-hoc analysis of a randomized controlled trial: diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly","volume":"35","author":"Huijts","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100007_b0135","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1128\/CVI.00288-15","article-title":"Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes","volume":"22","author":"Seo","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jvacx.2019.100007_b0140","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/thoraxjnl-2012-203109","article-title":"Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study","volume":"68","author":"Lau","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jvacx.2019.100007_b0145","article-title":"2015\/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project","volume":"22","author":"Rondy","year":"2017","journal-title":"Euro Surveillance: Bull Eur sur les Maladies Transmissibles = Euro Communicable Dis Bull"},{"key":"10.1016\/j.jvacx.2019.100007_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jvacx.2019.100007_b0155","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4161\/hv.6.11.12852","article-title":"Concomitant administration of zoster and pneumococcal vaccines in adults >\/=60 years old","volume":"6","author":"MacIntyre","year":"2010","journal-title":"Human Vaccines"},{"key":"10.1016\/j.jvacx.2019.100007_b0160","doi-asserted-by":"crossref","first-page":"M59","DOI":"10.1093\/gerona\/54.2.M59","article-title":"Relationship between the response to influenza vaccination and the nutritional status in institutionalized elderly subjects","volume":"54","author":"Fulop","year":"1999","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jvacx.2019.100007_b0165","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2019.100007_b0170","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259013621930004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259013621930004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:02:19Z","timestamp":1762912939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259013621930004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":34,"alternative-id":["S259013621930004X"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2019.100007","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2019.100007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100007"}}